When stopping weekly Actonel (risedronate), when should the first dose of denosumab be given?

Timing of Denosumab Initiation After Stopping Weekly Actonel

Start denosumab immediately after stopping weekly Actonel (risedronate) without any washout period.

Rationale for Immediate Transition

The key principle here is that bisphosphonates like risedronate have prolonged skeletal retention and residual antiresorptive effects that persist after discontinuation 1. Unlike switching from denosumab to a bisphosphonate (where immediate transition is critical to prevent rebound bone loss), the reverse transition does not carry the same urgency or risk.

However, given that:

• Risedronate has a terminal half-life of 561 hours in bone 1
• The drug continues to exert antiresorptive effects even after stopping
• Denosumab should not be delayed once the decision to start is made 2

The optimal approach is to begin denosumab at the next scheduled 6-month interval without waiting for risedronate to "wash out."

Practical Implementation

• If the patient took their last weekly Actonel dose on Sunday, schedule the first denosumab injection within 1-4 weeks
• There is no need to wait for bone turnover markers to normalize
• Ensure adequate calcium and vitamin D supplementation before starting denosumab 2
• Check and correct any hypocalcemia or vitamin D deficiency before the first denosumab dose 3

Critical Safety Considerations

Before Starting Denosumab:

• Verify adequate calcium levels (denosumab carries a 0.05-25% risk of hypocalcemia depending on renal function) 2
• Ensure vitamin D sufficiency
• Assess renal function (higher hypocalcemia risk with CKD) 2

After Starting Denosumab:

• Denosumab injections must be given every 6 months (±3 weeks) without fail 2, 3
• Never allow a "drug holiday" with denosumab 2
• If denosumab is ever discontinued, immediately transition to a potent bisphosphonate (zoledronate or alendronate) to prevent severe rebound bone loss and vertebral fractures 2, 3

Why Not Wait?

Unlike the reverse scenario (stopping denosumab requires immediate bisphosphonate coverage), stopping a bisphosphonate to start denosumab does not create a vulnerable window because:

• Risedronate remains in bone for months after discontinuation 1
• There is no "rebound effect" when stopping bisphosphonates
• Delaying denosumab only postpones the superior BMD gains and fracture reduction it provides 4, 5, 6, 7

The evidence shows denosumab is superior to risedronate for increasing BMD at all skeletal sites 4, 5, 6, 7, so prompt initiation maximizes patient benefit without introducing risk.